MIRECC / CoE

The main outcomes of the PRIME Care study were published in the Journal of the American Medical Association in July 2022. We will continue to post links to future findings on this website.

The purpose of this study was to determine the effectiveness of providing depressed Veterans and their providers the results of pharmacogenetic (PGx) testing for psychotropic medications. The study focused on whether and how patients and providers use genetic test results given to them at the time an antidepressant is to be initiated to treat Major Depressive Disorder (MDD) and whether use of the test results improves patient outcomes. MDD is one of the most common conditions associated with military service and combat exposure, increases suicide risk, and worsens the course of common medical conditions, making it a leading cause of disability and mortality. Validation of a PGx test to personalize the treatment of MDD represents an important opportunity to improve the health care of Veterans. Veteran recruitment took place at many VA sites. 

To find out which VA Medical Centers are participating in this study and the local contact information for each, click here.

ClinicalTrials.gov ID: NCT03170362